Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
The SNP identified in the SCN1A gene can be used as a genotype test to aid in the correct dosing of anti-epileptic drugs thereby avoiding debilitating adverse drug effects. More
A Robarts' Scientist has identified a target molecule that can serve as a switch between scar establishment and regenerative matrix deposition by astroctye cells. More
These compounds have demonstrated high affinity and selectivity for the dopamine transporter over other monoamine transponders as well as muscarinic receptors, without a significant cocaine-like behavioral profile. More
Initial results indicate that sodium nitrite can be used as a potential cost-effective platform therapy for a wide variety of disease indications characterized broadly by constricted blood flow or hypoxia. More
Biomarker and possible therapeutic target for a variety of neurodegenerative diseases More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Attention-deficit/hyperactivity disorder
- Autism
- Brain injury
- Cerebral palsy
- Cerebrovascular disorders
- Dyslexia
- Emesis
- Encephalitis
- Epilepsy
- Huntington's disease
- Hypersomnia
- Insomnia
- Meningitis, aseptic
- Meningitis, bacterial
- Meningitis, viral
- Migraine
- Myalgic encephalomyelitis
- Narcolepsy
- Neoplastic meningitis
- Nerve regeneration
- Neuropathy, AIDS-related
- Neuropathy, diabetic
- Neuropathy, peripheral
- Neuroprotection
- Premenstrual dysphoric disorder
- Sleep apnea
- Sleep disorders
- Spasticity
- Spinal cord injury
- Stroke
- Tourette's syndrome
- Vertigo
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us